Chemotherapy,
Год журнала:
2019,
Номер
64(2), С. 62 - 80
Опубликована: Янв. 1, 2019
Background:
Immune
checkpoints
are
critical
regulatory
pathways
of
the
immune
system
which
finely
tune
response
to
biological
threats.
Among
them,
CD-28/CTLA-4
and
PD-1/PD-L1
axes
play
a
key
role
in
tumour
escape
well-established
targets
cancer
immunotherapy.
Summary:
The
clinical
experience
accumulated
date
provides
unequivocal
evidence
that
anti-CTLA-4,
PD-1,
or
PD-L1
monoclonal
antibodies,
used
as
monotherapy
combination
regimes,
effective
variety
advanced/metastatic
types
cancer,
with
improved
outcomes
compared
conventional
chemotherapy.
However,
therapeutic
success
is
currently
restricted
limited
subset
patients
reliable
predictive
biomarkers
still
lacking.
Key
Message:
identification
characterization
additional
co-inhibitory
novel
pharmacological
improve
refractory
has
led
development
different
checkpoint
inhibitors,
activities
under
investigation.
In
this
review,
we
discuss
recent
literature
data
concerning
mechanisms
action
next-generation
antibodies
targeting
LAG-3,
TIM-3,
TIGIT
molecules
being
explored
trials,
single
agents
other
immune-stimulating
agents.
Phototherapy
is
an
emerging
approach
for
cancer
treatment
that
effective
at
controlling
the
growth
of
primary
tumors.
In
presence
light
irradiation,
photothermal
and
photodynamic
agents
are
delivered
to
tumor
sites
can
induce
local
hyperthermia
production
reactive
oxygen
species,
respectively,
directly
eradicate
cells.
Nanoparticles,
characterized
by
their
small
size
tunable
physiochemical
properties,
have
been
widely
utilized
as
carriers
phototherapeutic
improve
biocompatibility
tumor-targeted
delivery.
Nanocarriers
also
be
used
implement
various
codelivery
strategies
further
enhancing
efficiency.
More
recently,
there
has
considerable
interest
in
augmenting
immunological
effects
nanoparticle-based
phototherapies,
which
yield
durable
systemic
antitumor
responses.
This
review
provides
overview
recent
developments
using
nanoparticle
technology
achieve
photo-immunotherapy.
Pharmaceutics,
Год журнала:
2023,
Номер
15(9), С. 2223 - 2223
Опубликована: Авг. 29, 2023
Due
to
the
diverse
medicinal
and
pharmacokinetic
properties
of
turmeric,
it
is
well-known
in
therapeutic,
pharmaceutic,
nutraceutical,
cosmetic,
dietary
industries.
It
gained
importance
due
its
multitude
properties,
such
as
wound-healing,
anti-inflammatory,
anti-oxidant,
anti-microbial,
cytoprotective,
anti-aging,
anti-cancer,
immunomodulatory
effects.
Even
though
natural
healing
effect
turmeric
has
been
known
Indians
early
2500
BCE,
global
demand
for
increased
only
recently.
A
major
reason
beneficiary
activities
presence
yellow-colored
polyphenolic
compound
called
curcumin.
Many
studies
have
carried
out
on
various
curcumin
derivatives.
Despite
low
bioavailability,
effectively
used
treatment
many
diseases,
cardiovascular
neurological
diabetes,
arthritis,
cancer.
The
advent
nanobiotechnology
further
opened
wide
opportunities
explore
expand
use
medical
field.
Nanoformulations
using
derivatives
helped
design
new
modalities,
specifically
cancer,
because
better
bioavailability
solubility
nanocurcumin
when
compared
This
review
deals
with
applications
nanoparticles
cancer
therapy
broadly
tries
understand
how
affect
immunological
status
cell.
Journal of Crohn s and Colitis,
Год журнала:
2019,
Номер
14(6), С. 831 - 840
Опубликована: Окт. 30, 2019
Abstract
Background
and
Aims
Interleukin
6
[IL-6]
or
its
receptor
is
currently
a
candidate
for
targeted
biological
therapy
of
inflammatory
bowel
disease
[IBD].
Thus,
comprehensive
understanding
the
consequences
blocking
IL-6
imperative.
We
investigated
this
by
evaluating
effects
deletion
on
spontaneous
colitis
IL-10-deficient
mice
[IL-10−/−].
Methods
IL-6/IL-10
double-deficient
[IL-6−/−/IL-10−/−]
were
generated
analysed
intestinal
inflammation,
general
phenotypes
molecular/biochemical
changes
in
colonic
mucosa
compared
with
wild-type
IL-10−/−
mice.
Results
Unexpectedly,
IL-6−/−/IL-10−/−
showed
more
pronounced
gut
inflammation
earlier
onset
than
mice,
both
locally
[colon
small
bowel]
systemically
[splenomegaly,
ulcerative
dermatitis,
leukocytosis,
neutrophilia
monocytosis].
exhibited
elevations
multiple
cytokines
[IL-1β,
IL-4,
IL-12,
TNFα]
chemokines
[MCP-1
MIG],
but
not
IFN-γ
[Th1],
IL-17A
IL-17G
[Th17],
IL-22
[Th22].
FOXP3
TGF-β,
two
key
factors
regulatory
T
[Treg]
cell
differentiation,
significantly
down-regulated
mucosa,
thymus
mesenteric
lymph
nodes,
CTLA-4
was
diminished
while
iNOS
up-regulated
Conclusion
In
complete
blockade
aggravates
at
least
part
suppressing
Treg/CTLA-4
promoting
IL-1β/Th2
pathway.
addition,
double
mutant
exhibits
signs
severe
systemic
inflammation.
Our
data
define
new
function
suggest
that
caution
should
be
exercised
when
targeting
IBD
patients,
particularly
those
defects
IL-10
signalling.
Chemotherapy,
Год журнала:
2019,
Номер
64(2), С. 62 - 80
Опубликована: Янв. 1, 2019
Background:
Immune
checkpoints
are
critical
regulatory
pathways
of
the
immune
system
which
finely
tune
response
to
biological
threats.
Among
them,
CD-28/CTLA-4
and
PD-1/PD-L1
axes
play
a
key
role
in
tumour
escape
well-established
targets
cancer
immunotherapy.
Summary:
The
clinical
experience
accumulated
date
provides
unequivocal
evidence
that
anti-CTLA-4,
PD-1,
or
PD-L1
monoclonal
antibodies,
used
as
monotherapy
combination
regimes,
effective
variety
advanced/metastatic
types
cancer,
with
improved
outcomes
compared
conventional
chemotherapy.
However,
therapeutic
success
is
currently
restricted
limited
subset
patients
reliable
predictive
biomarkers
still
lacking.
Key
Message:
identification
characterization
additional
co-inhibitory
novel
pharmacological
improve
refractory
has
led
development
different
checkpoint
inhibitors,
activities
under
investigation.
In
this
review,
we
discuss
recent
literature
data
concerning
mechanisms
action
next-generation
antibodies
targeting
LAG-3,
TIM-3,
TIGIT
molecules
being
explored
trials,
single
agents
other
immune-stimulating
agents.
